MOTS-c Peptide: Cannot Be Ordered or Prescribed
You cannot order or prescribe MOTS-c peptide for your patient because it is not FDA-approved for any clinical indication and remains an investigational compound.
Regulatory Status
The FDA drug label provided 1 is actually for folic acid, not MOTS-c—this appears to be a database error. MOTS-c has no FDA approval, no established dosing guidelines, no safety profile for clinical use, and no quality-controlled pharmaceutical formulation available for prescription.
What MOTS-c Actually Is
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA region of the mitochondrial genome 2. While research shows it functions as:
- A mitochondrial-encoded host defense peptide with antibacterial and immunomodulatory properties 3
- A metabolic regulator that enhances glucose metabolism and insulin sensitivity 4
- A potential therapeutic agent in preclinical models of diabetes, cancer pain, and ischemic tissue injury 5, 6, 7
All of this evidence comes exclusively from animal models and in vitro studies—there are no completed human clinical trials demonstrating safety or efficacy.
Why This Matters Clinically
Safety Concerns
- No established human safety data exists
- No known drug interactions have been characterized
- Long-term effects are completely unknown
- The peptide's effects on liver, renal, lipid, and cardiac function have only been assessed in mice 6
Legal and Liability Issues
- Prescribing non-FDA-approved compounds exposes you to significant medicolegal risk
- No standardized pharmaceutical-grade product exists
- Patients may be obtaining this from unregulated compounding pharmacies or online sources with unknown purity and contamination risks
The Research Reality
While studies show promising preclinical results in gestational diabetes 4, type 2 diabetes 5, and other conditions, these are early-stage animal studies. The most recent human data 8 actually showed that metformin treatment in breast cancer patients did not significantly alter circulating MOTS-c levels, highlighting how little we understand about this peptide's regulation in humans.
What to Tell Your Patient
Be direct: "MOTS-c is not an FDA-approved medication. It's currently only being studied in laboratory and animal research. I cannot legally prescribe it, and any source offering it is not providing a regulated pharmaceutical product. The safety and effectiveness in humans are unknown."
If the patient has the underlying condition that prompted their interest (diabetes, metabolic syndrome, etc.), redirect them to evidence-based treatments with established safety profiles and proven clinical benefit.
Common Pitfall
Do not be swayed by the volume of recent research publications or the patient's enthusiasm about "cutting-edge" peptide therapy. Research interest does not equal clinical readiness. The pathway from promising preclinical data to FDA approval typically takes years of human trials to establish safety and efficacy.